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Abstract. 
Enteroaggregative Escherichia coli (EAEC) cause acute and persistent diarrhea, mostly in children worldwide. 
Outbreaks of diarrhea caused by EAEC have been described, including a large outbreak caused by a Shiga toxin 
expressing strain. This study investigated the association of EAEC virulence factors with diarrhea in children 
less than 5 years. We characterized 428 EAEC strains isolated from stool samples obtained from moderate-to-
severe diarrhea cases (157) and healthy controls (217) children aged 0–59 months recruited over 3 years as part 
of the Global Enteric Multicenter Study (GEMS) in The Gambia. Four sets of multiplex polymerase chain 
reaction were applied to detect 21 EAEC-virulence genes from confirmed EAEC strains that target pCVD432 
(aatA) and AAIC (aaiC). In addition, Kirby-Bauer disc diffusion antimicrobial susceptibility testing was 
performed on 88 EAEC strains following Clinical Laboratory Standard Institute guidelines. We observed that 
the plasmid-encoded enterotoxin [odds ratio (OR): 6.9, 95% confidence interval (CI): 2.06–29.20, P < 0.001], 
aggregative adherence fimbriae/I fimbriae (aggA) [OR: 2.2, 95% CI: 1.16–4.29, P = 0.008], and 
hexosyltransferase (capU) [OR: 1.9, 95% CI 1.02–3.51, P = 0.028] were associated with moderate-to-severe 
diarrhea among children < 12 months old but not in the older age strata (> 12 months). Our data suggest that 
some EAEC-virulent factors have age-specific associations with moderate-to-severe diarrhea in infants. 
Furthermore, our study showed that 85% and 72% of EAEC strains tested were resistant to sulphamethoxazole-
trimethoprim and ampicillin, respectively. Sulphamethoxazole-trimethoprim and ampicillin are among the first-
line antibiotics used for the treatment of diarrhea in The Gambia. 
INTRODUCTION 
Enteroaggregative Escherichia coli (EAEC) is an important causative agent of both acute 
and persistent diarrhea among adults and children worldwide1 and it has been among the most 
common E. coli pathotypes causing diarrhea among children less than 5 years of age in some 
developing countries.2 Several outbreaks of EAEC diarrhea have been reported in both 
developed and developing nations and infants are the most affected.3–6 EAEC has been 
implicated in travelers’ diarrhea7,8 and persistent diarrhea among human immunodeficiency 
virus–infected individuals.9 This pathotype was implicated in a massive outbreak of 
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hemolytic uremic syndrome in Germany in 2011.10 The clinical presentation of EAEC 
infection is characterized by watery and mucoid diarrhea with low-grade fever and 
insignificant vomiting.11,12 
The pathogenesis of EAEC diarrhea is thought to comprise colonization of the intestinal 
mucosa, followed by elaboration of enterotoxins and cytotoxins and the release of 
proinflamatory cytokines from infected epithelial cells,13,14 induced by the EAEC adherence 
factors called aggregative adherence fimbriae (AAF). In addition, EAEC strains 
characteristically enhance mucus secretion from the mucosa, potentially trapping the 
bacterium in a bacterium-mucus biofilm.1 A distinctive feature of EAEC is its ability to elicit 
characteristic stacked brick-liked aggregative adherence to HEp-2 or HeLa cells, a test that 
remains the gold standard to identify this pathotype.15 EAEC strains express several genes 
that may confer virulence and are highly heterogeneous regarding the combination of these 
virulence genes, which are encoded on the bacterial chromosome or on an EAEC-specific 
plasmid-designated pAA. The majority of EAEC strains harbor a transcriptional activator of 
the AraC/XyIS called AggR, which control genes on both the plasmid and the chromosome. 
Among the genes under AggR control includes those that encode the AAF where at least five 
variants exist. These genes encoding the major structural pilin subunits are designated as 
aggA (AAF/I), aafA (AAF/II), agg3A (AAF/III), agg4A (AAF/IV), and agg5A (AAF/V).16–18 
Other plasmid-borne potential virulence factors include the EAEC heat-stable enterotoxin 1 
(EAST1) (encoded by the astA gene),19 an anti-aggregation protein called dispersin (encoded 
by the aap gene), and a transporter apparatus for dispersin called Aat (encoded by the aat 
genes). EAEC frequently harbor members of the serine protease autotransporters of 
Enterobacteriaceae (SPATEs), which have been described as enterotoxins and cytotoxins. 
The heat-labile enterotoxin/cytotoxin called Plasmid-encoded toxin (Pet)20 has been 
implicated in causing cytotoxic effects on the human intestinal mucosa. Other SPATEs 
carried by EAEC strains include the cryptic protease called SepA, and the mucinase called 
Pic (protein involved in intestinal colonization),21,22 which is encoded on the chromosome. 
Other important chromosomal gene that encodes virulence markers include 1) Irp2 (iron 
repressible high-molecular-weight protein 2) a protein responsible for yersiniabactin 
biosynthesis and 2) flagellin, which interacts with the epithelial cells, leading to the secretion 
of an intestinal interleukin-8.23 The EAEC genome has been found to be markedly mosaic; 
thus, the various putative virulence factors are found inconsistently among individual strains, 
suggesting that some strains considered EAEC may be truly virulent, and others not.20 
Several studies have shown that EAEC is the most frequently detected E. coli pathotype 
in humans, particularly among children from both developed and developing countries.24–26 
The Global Enteric Multicenter Study (GEMS) comprised identical case–control studies of 
moderate-to-severe diarrhea (MSD) among children under 5 years of age at four sites in sub-
Saharan Africa and three in south Asia showing high frequency of EAEC.27 Although EAEC 
was not associated with MSD disease in the GEMs study, a subsequent analysis of the 
association of individual EAEC genes alone and in combination among EAEC isolates from 
MSD cases and controls of GEMS in Mali by Boisen found that SepA protease was 
associated with MSD.28 In the study presented, we replicated the analysis by Boisen, scoring 
the presence of 21 putative EAEC virulence factors from 428 EAEC isolates randomly 
selected among 741 EAEC isolates obtained from diarrheal and nondiarrheal children 
enrolled in the GEMS study to characterize the virulence genes in children from The Gambia. 
We analyzed these EAEC virulence genes by age strata (0–11, 12–23, and 24–59 months). 
Furthermore, antimicrobial resistance patterns were investigated on a 20% of the EAEC 
strains selected at random. 
Page 3 of 17 
MATERIALS AND METHODS 
Patients and enteric pathogens tested. 
The study participants were enrolled as part of the 3-year (December 2007 to December 
2010) prospective case–control GEMS in The Gambia. The clinical and microbiologic 
methods for the GEMS have been published.29 In GEMS, children aged 0- to 59-month old 
from a defined census population attending to sentinel health center with sign of MSD were 
enrolled. One to three healthy controls matched by age, sex, and community were recruited 
within 14 days after the enrolment of cases.30 As part of the main study, stool samples were 
processed for enteric bacterial pathogens (including E. coli, Salmonella spp., Shigella spp., 
Vibrio spp., Campylobacter spp., and Aeromonas spp.), Viruses (Sapovirus, Norovirus, and 
Rotavirus), and parasites (Giardia lamblia, Cryptosporidium species, and Entamoeba 
histolytica).31 A total of 2,598 children were enrolled in The Gambia and 741 (28.5%) 
children had EAEC isolated (278 cases and 463 controls). 
For this ancillary study, the matching design was not maintained. We randomly selected 
428 (58%) of the participants with samples positive for EAEC (157 cases and 271 controls) 
(Table 1) to conduct genotypic characterization of the 21 virulence factors. Of the 157 cases, 
94 (60%) and 63 (40%) account for male and female, respectively, whereas among the 
controls 151 (56%) account for male and 120 (44%) account for female. 
Testing of 21 enteroaggregative E. coli virulence genes. 
From an overnight growth on MacConkey agar (Oxoid, Hampshire, United Kingdom), 
three suspected colonies of E. coli (typically lactose fermenting) for each patient were 
purified and identified as E. coli using the biochemical reagent kit Analytical Profile Index 20 
E (BioMeriux Ltd, Hampshire, United Kingdom). The resultant confirmed E. coli were 
screened to detect EAEC, ETEC, and EPEC pathotypes using a multiplex polymerize chain 
reaction (PCR) GEMS protocol.31 In this study, we performed monoplex PCR on each 
isolates that has initially showed presence of EAEC in GEMS E. coli multiplex PCR 
protocol. The target sought for EAEC are the EAEC plasmid-encoded gene aatA (primer 
CVD432F–sequence 5-CTGGCGAAAGACTGTATCAT-3and primer CVD432R–sequence 
5-CAATGTATAGAAATCCGCTGTT-3) and the EAEC chromosomally encoded aaiC 
(primer AAIC F–sequence 5-ATTGTCCTCAGGCATTTCAC-3 and primer AAIC R-
sequence 5-ACGACACCCCTGATAAACAA-3, these two loci are known as virulence 
determinants. EAEC colonies were investigated for the presence of the 21 putative virulence 
genes using four multiplex PCRs as previously described.28 The 21 genes were grouped into 
four. On each group, multiplex PCR was performed. On group 1 (sat, sepA, pic, sigA, 
plasmid-encoded enterotoxin [pet], and astA), multiplex PCR master mix was achieved using 
Qiagen kit (Catalogue no. 206143) following the manufacturer’s instructions. Multiplex PCR 
assay was performed in a final reaction volume of 25 µL consists of 12.5 µL mastemix 
(MM), 2.5 µL Q-solution, 6 µL primer (MM), 2.5 µL H2O, and 1.5 µL DNA template. PCR 
reaction cycles were as follows: 15 minutes preheating at 95°C at the start, 50 seconds 
denaturation at 94°C, annealing for 1.5 minutes, and extension at 72°C for 1.5 minutes with 
35 cycles returning to step 2. The final extension was 10 minutes at 72°C. 
On group 2 (aatA, aggR, aaiC, aaP, and ORF3), group 3 (aafC, agg3/4C, agg3A, aafA, 
aggA, and agg4A), and group 4 (air, capU, ailA, and ORF61) Fementers kit (Catalogue no. 
K0171) was used for the PCR master mix (2X) following the manufacturer’s instructions. 
Multiplex PCR assay was achieved in a final reaction volume of 25 µL that compose of 12.5 
µL (MM), 1 µL (25 mM magnesium chloride), 5 µL primer (MM), 5 µL H2O, and 1.5 µL 
DNA template. PCR reaction cycles were achieved as follows: 2 minutes preheating at 95°C 
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at the start, 50 seconds denaturation at 94°C, annealing at 57°C (58°C for groups 3 and 4) for 
1.5 minutes, and extension at 72°C for 1.5 minutes with 35 cycles returning to step 2. The 
final extension was 10 minutes at 72°C. 
Amplifications were performed using Thermocycler (TECHNE Flexigen, Model 
FFG02FSD, Serial 11733-1). Amplified PCR products were analyzed on a 2% agarose gel 
containing ethidium bromide (0.1 m ml-1 in 1  TBE buffer and visualized on the 2% [w/v] 
agarose gel under ultraviolet radiation. The gel images were captured digitally with a gel 
documentation system. 
The E. coli strains used as controls for detection of the target genes are C1010-00 (sat, 
sepA, agg3/4C, and agg4A), JM221 (sat and aggA), 042 (pic, pet, astA, aatA, aggR, aaiC, 
aap, ORF3, aafC, aaFA, air, capU, and eilA), 55989 (sigA, agg3A/4C, and agg3A), 63 (sigA, 
agg3/4C, and agg4A), and 17-2 (aggA). GIBCO distilled water (DNase/RNase free, 
Catalogue no. 10977-035) was used as negative control. 
Antimicrobial assay. 
For antimicrobial susceptibility testing, 88 EAEC isolates were randomly selected from 
the 428 EAEC isolates used for the virulence genes assay. Disk diffusion (Kirby Bauer) 
method for susceptibility testing that allows categorization of bacterial isolates as susceptible, 
resistant, or intermediate to eight commercially acquired antimicrobial agents which include 
ampicillin 10 µg, cotrimoxazole 25 µg, tetracycline 30 µg, ceftazidime 30 µg, ciprofloxacin 5 
µg, ceftriaxone 30 µg, cefoxitin 30 µg, and nalidixic acid 30 µg (Oxoid) were used. The 
Clinical Laboratory Standard Institute version M100-S22, Vol. 32, No. 3, 2012, guidelines 
were followed. E. coli ATCC 25922 was used for quality control antibiotic susceptibility 
assay. 
Ethical consideration. 
The GEMS obtained ethical clearance from The Gambian Government/Medical Research 
Council (MRC) Ethics committee following the scrutiny of the study proposal by the MRC 
Scientific Coordinating Committee. 
Statistical analyses. 
Bivariate analysis was applied to compare prevalence of virulence factors between cases 
and controls in different age group using STATA 12 reporting odds ratios (ORs) with 95% 
confidence intervals (CIs). A two-sided P value < 0.05 was considered statistically 
significant. 
In addition, we used Classification and Regression Tree (CART) pro-Version 6.0 (Salford 
Systems) software to input 21 factors of interest as binary (present/absent) independent 
variables. Although, case–control status was input as the binary dependent outcome variable. 
Significance of combinations of EAEC genes. 
We generated a virulence factor score (VFS), representing the collective number of 
virulence loci present in each strain. To consider the combination factors, we used CART 
analysis (Supplemental Figures 1 and 2), which builds a model in stepwise fashion to yield 
the combination of factors most strongly associated with the queried outcome. Each branch of 
a CART output tree ends in a terminal “node”; each observation falls into exactly one 
terminal node; and each terminal node is uniquely defined by a set of rules, such as having or 
not having a certain factor. 
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We considered all genotypic and phenotypic assays performed and considered the 
association with case status versus control status (Supplemental Figures 1 and 2). 
RESULTS 
Among all EAEC strains in cases and controls (N = 428), the age and sex distribution 
were similar among cases and controls except for a lower prevalence of children above 23 
months among cases (Table 1). Overall, orf61 (aar) was the most commonly detected gene, 
(69.6%). This was followed by the cryptic ORF3 (64%), capU (62%), aggR (60.1%), astA 
(51.4%), eilA (48.3%), and aap (46.3%); the rest of the genes were present in less than 40% 
of isolates (Table 2). Analysis of the EAEC virulence genes in all age groups together, 
showed that only four of the 21 genes assayed (sepA, pet, astA, and capU) were more 
prevalent among cases. Prevalence of AAF/I encoded by aggA gene was slightly higher in 
cases than controls (29.9% versus 22.9%) (OR: 1.4, 95% CI: 0.89–2.29, P = 0.106) (Table 2). 
The frequency of other AAF pilin genes, AAF/II (aafA), and AAF/III (agg3A) were low in 
both cases and controls but slightly high for AAF/IV (agg4A) in cases compared with 
controls. However, the AAF usher-encoding gene agg3/4C was similar in cases and controls 
(36.9% versus 35.4%, respectively). Of the five SPATE genes (sat, pet, sigA, pic, and sepA), 
prevalence of sepA (OR: 1.6, 95% CI: 0.99–2.49, P = 0.041) and pet (OR: 1.9, 95% CI: 0.97–
3.56, P = 0.042) genes were higher among diarrhea cases (Table 2). 
The distribution of the characterized virulence genes varied across the age strata. In 0- to 
11-month stratum, prevalence of pet (OR: 6.9, 95% CI: 2.06–29.20, P < 0.001), aggA (OR: 
2.2, 95% CI: 1.16–4.29, P = 0.008), and capU (OR: 1.9, 95% CI: 1.02–3.51, P = 0.028) 
genes were more common in cases compared with controls (Table 3). Similar higher 
prevalence pattern was observed for pet (OR: 15.0, 95% CI: 1.35–750.0, P = 0.003) and 
capU (OR: 4.3, 95% CI: 1.27–18.54, P = 0.009) when the virulence factors were 
characterized among the sole EAEC pathogen from MSD children 0- to 11-month age in 
cases than controls. 
Prevalence of virulence genes that were proportionately higher in cases compared with 
controls in children 0–11 months were sepA (36.5% versus 26.5%), astA (54.1% versus 
41.7%), aggR (71.8% versus 62.1%), aap (56.5% versus 44.7%), and ORF3 (75.3% versus 
63.6%). The astA gene was found more often in cases (67.2%) than in controls (49.5%) in the 
age stratum 12–23 months (OR: 2.1, 95% CI1.03–4.27, P = 0.026); none of the putative 
virulence factors were found to be significantly more common in MSD children  2 years of 
age (Table 3). 
In addition to considering each factor individually, we considered the importance of 
combinations of potential EAEC virulence factors by employing CART analysis. The CART 
analysis builds a model in stepwise fashion to yield the combination of factors most strongly 
associated with the queried outcome, in this case the combination of factors most strongly 
associated with MSD. Each branch of a CART output tree ends in a terminal “node”; each 
observation falls into exactly one terminal node; and each terminal node is uniquely defined 
by a set of rules, such as having or not having a certain factor. 
We examined all genotypic assays performed: aatA, aggR, aaiC, aap, ORF3, sat, sepA, 
pic, sigA, pet, astA, aafC, agg3/4C, aafA, agg3A, aggA, agg4A, air, capU, eilA, aar, as well 
as considering the collective number of virulence loci present (generating a VFS) 
(Supplemental Figures 1 and 2). 
As noted, prevalence of the virulence were significantly higher in cases compared with 
controls in children 0–11 months and applying the CART analysis (Supplemental Figure 2) 
showed that the presence of pet (Node 1), regardless of the presence or absence of any other 
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scored genotype among the pet-positive strains, provided a strong association with diarrhea. 
Among the pet-negative strains, CART analysis suggested two additional trait clusters that 
were associated with MSD: Node 2 includes those strains with a VFS  8 in combination 
with sepA, whereas Node 3 includes a VFS > 8, suggesting a combination of typical EAEC 
factors in addition to the toxin EAST-1 toxin. 
Antibiotic susceptibility testing. 
The susceptibility patterns of the randomly selected 88 (20%) EAEC strains were similar 
among cases and controls. The data showed that all the randomly selected 88 (100%) EAEC 
strains tested were susceptible to ceftriaxone and cefoxitin, over 90% were susceptible to 
cefotazidime and ciprofloxacin, and more than 80% were susceptible to chloramphenicol and 
nalidixic acid. However, susceptibility to sulphamethoxazole-trimethoprim and ampicillin 
was low (15% and 28%, respectively) (Table 4). 
DISCUSSION 
EAEC is a common cause of diarrhea worldwide.32 The assessment of the 21 genes in the 
428 EAEC strains in this study showed that the frequency of most genes correlated well with 
similar studies, particularly the study from the GEMS neighboring site, in Bamako Mali.28 In 
this study, more than half of participants were younger than 1 year of age, although there 
were no differences between cases and controls. Particularly, striking was the consistency of 
the association between SepA and MSD in Mali and this study. SepA is a SPATE protease 
that was initially found in Shigella flexneri strains,33 but has subsequently been found 
commonly among EAEC.34 The protease has been implicated in causing increased 
inflammation in Shigella strains but it may also have enterotoxic activity. 
In this study, the virulence genes aggA encoding for AAF/1, capU, and pet, encoding a 
member of Class 1 SPATEs family, were statistically implicated as genes responsible for 
EAEC diarrhea in younger children < 12 months. 
Our study highlights significant heterogeneity in gene profiles among the EAEC isolates. 
Of the 21 genes targeted, none of the EAEC isolates characterized genetically harbors more 
than 15 genes. The heterogeneous nature of EAEC enables it to display variation in causing 
clinical illness,32 although factors responsible for its virulence are not well understood. 
Several studies have shown possible genes that confer virulence on EAEC.32,35 Our data 
show three virulence genes associated with diarrhea in infants. Interestingly, the three 
incriminated virulence genes are plasmid genes that include pet, AAF/1 fimbrial subunit 
(aggA), and hexosyltransferase homolog (capU). The Pet toxin is a 108-kDa protease 
implicated in cytoskeletal changes and epithelial-cell rounding by cleavage of the 
cytoskeletal protein spectrin.36–39 In Mexico, the Pet gene was initially detected from EAEC 
strain 049766 implicated in a highly virulent outbreak of diarrhea in which some infants 
died.40 Also, the reported enterotoxic activity of EAEC induced by Pet is consistent with the 
secretory diarrhea seen in most patients with EAEC enteritis.41 A recent report from Iran 
alluded that pet gene is more prevalent among EAEC strains isolated from adult diarrheal 
patients.42 Therefore, our findings support the role of Pet gene in EAEC causing diarrhea in 
infants (Supplemental Figure 1; Table 3). However, earlier EAEC virulence factor study 
conducted in southwest Nigeria over a decade ago showed that the Pet gene was equally 
distributed among EAEC strains isolated from children < 5 years with or without diarrheal.43 
Seemingly, our study also showed, no association of Pet with diarrheal disease in the children 
< 5 years but the effect is only seemed in EAEC strains isolated from children < 1 year and so 
the differences between our findings could be due to age stratification. 
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AAF/I was associated with diarrhea in the first year of life. The Shiga toxin producing 
EAEC strain implicated in the German outbreak expressed AAF/I.44 
Hexosyltransferase homolog (capU), a plasmid-encoded protein was significantly high 
among the younger children. Its role in EAEC diarrhea is not clearly defined. Notably, the 
capU gene was the third most common gene found (62%) among genes investigated in this 
study. This probably highlights the importance of genes acting in concert. 
astA encodes an EAST1 that is related to the heat-labile enterotoxin of enterotoxigenic E. 
coli. The relevance of astA gene in EAEC diarrhea has been reported in several studies,45–48 
and EAST1 was found to be associated with diarrhea in combination with other genes in the 
Mali study.28 astA is not restricted to EAEC but is widely distributed among other enteric 
pathogens49,50 as well as commensal E. coli. 
Globally, EAEC strains have shown a low to high level of resistance to antimicrobial 
agents.51 Our data from the antimicrobial susceptibility investigation highlights resistant 
pattern of the EAEC strains against cotrimoxazole and ampicillin. The first line of antibiotics 
prescribed for patient management in our region is cotrimoxazole and ampicillin, which 
explains the high resistance against these antibiotics. An increase in resistance of EAEC 
strains to chloramphenicol, nalidixic acid, and quinolones was observed in this study 
compared with a similar study on a member of enterobacteriaceae family from the same 
region52 and in eastern Asia.53 Twenty percent of the EAEC strains tested showed multidrug 
resistance to three antimicrobial agents, whereas 6% showed resistance to more than three 
antimicrobial agents. This finding is in contrast to a similar study conducted in India, 
showing 75% of strains with multidrug resistance, that is, > 3 antimicrobial agents.54 
The limitations of this study included exclusion of multiple comparisons such as 
malnutrition and other enteric coinfections. Hence, future studies can consider these essential 
confounders. 
Our study has strengthened the role of pet and aggA genes of EAEC in the cause of MSD 
in African infants. The EAEC virulence gene profiles found in this study have also proven the 
heterogeneity of the genetic component of the EAEC isolates studied. However, further 
investigations are needed to establish the specific or combination of gene(s) that are 
associated with EAEC diarrheal in different age strata, particularly children from developing 
countries. In addition, the pattern of antimicrobial resistance against EAEC is worrisome and 
needs to be addressed. 
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TABLE 1 
Baseline information of study population 
Demographic 
factors 
Case (N = 157) 
no. (%) 
Control (N = 271) no. 
(%) 
Total (N = 428) 
no. (%) OR (95% CI) P value 
Age (month) 
0–11 85 (54.1) 132 (48.7) 217 (50.7) 1.2 (0.82–1.88) 0.278 
12–23 61 (38.9) 105 (38.8) 166 (38.8) 1.0 (0.65–1.53) 0.982 
24–59 11 (7.0) 34 (12.6) 45 (10.5) 0.5 (0.23–1.10) 0.071 
CI = confidence interval; OR = odds ratio. 
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TABLE 2 
Distribution of EAEC virulence genes from case and control children (age 0–59 months) 
Gene class Virulence gene 
Case (N = 157) 
no. (%) 
Control (N = 271) 
no. (%) 
Total (N = 428) 
no. (%) OR (95% CI) 
2 P value 
 aatA 51 (32.5) 82 (30.3) 133 (31.1) 1.1 (0.71–1.73) 0.2 0.631 
 aggR 97 (61.8) 161 (59.4) 258 (60.3) 1.1 (0.72–1.69) 0.2 0.628 
 aaP 77 (49.0) 121 (44.7) 198 (46.3) 1.2 (0.78–1.80) 0.8 0.379 
 ORF3 106 (67.5) 168 (62.9) 274 (64.0) 1.3 (0.82–1.98) 1.3 0.251 
 capU 108 (68.8) 158 (58.3) 266 (62.2) 1.6 (1.02–2.45) 4.7 0.031 
 
 
aar 110 (70.1) 188 (69.4) 298 (69.6) 1.0 (0.66–1.63) 0.1 0.880 
pAA A aafC 7 (4.5) 16 (6.0) 23 (5.4) 0.7 (0.25–1.97) 0.4 0.522 
P D agg3/4C 58 (36.9) 96 (35.4) 154 (36.8) 1.1 (0.69–1.64) 0.1 0.752 
L H agg3A 10 (6.4) 28 (10.3) 38 (9.8) 0.6 (0.25–1.29) 1.9 0.164 
A E aafA 3 (1.9) 15 (5.5) 18 (4.2) 0.3 (0.06–1.20) 3.2 0.071 
S S aggA 47 (29.9) 62 (22.9) 109 (25.5) 1.4 (0.89–2.29) 2.6 0.106 
I M N agg4A 15 (9.6) 16 (6.0) 31 (7.2) 1.7 (0.74–3.75) 
1.9 0.160 
I T astA 91 (58.6) 129 (47.6) 220 (51.4) 1.5 (1.00–2.30) 4.3 0.038 
D O sat 29 (18.5) 56 (20.7) 85 (19.9) 0.9 (0.51–1.47) 0.3 0.583 
 X sepA 50 (31.9) 62 (22.9) 112 (26.2) 1.6 (0.99–2.49) 4.1 0.041 
 I pet 24 (15.3) 24 (8.9) 48 (11.2) 1.9 (0.97–3.56) 4.1 0.042 
CH N pic 55 (35.0) 88 (32.5) 143 (33.4) 1.1 (0.72–1.73) 0.3 0.588 
RO S sigA 18 (11.5) 31 (11.4) 49 (11.5) 1.0 (0.50–1.93) 0.0 0.993 
MO aaiC 44 (28.0) 97 (35.8) 141 (32.9) 0.7 (0.44–1.09) 2.7 0.099 
SO air 41 (26.1) 57 (21.0) 98 (22.9) 1.3 (0.81–2.15) 1.5 0.227 
ME 
 
eilA 79 (50.3) 128 (47.2) 207 (48.4) 1.1 (0.75–1.71) 0.4 0.538 
CI = confidence interval; EAEC = enteroaggregaive Escherichia coli; OR = odds ratio. 
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TABLE 3 
Distribution of EAEC virulence genes in case and control children in three age strata 
0–11 months (N = 217) 12–23 months (N = 166) 24–59 months (N = 45) 
Virulenc
e genes 
Case (N = 
85) no. 
(%) 
Control (N = 
132) no. (%) OR (95% CI) P value 
Case (N = 
61) no. 
(%) 
Control (N = 
105) no. (%) OR (95% CI) P value 
Case (N = 
11) no. 
(%) 
Control (N = 
34) no. (%) 
OR (95% CI) P value 
aatA 33 (38.8) 48 (36.4) 1.1 (0.60–2.02) 0.714 16 (26.2) 26 (24.8) 1.1 (0.48–2.34) 0.833 2 (18.2) 8 (23.5) 0.7 (0.06–4.71) 0.710 
aggR 61 (71.8) 82 (62.1) 1.5 (0.82–2.93) 0.143 33 (54.1) 62 (59.1) 0.8 (0.41–1.62) 0.534 3 (27.3) 17 (50.0) 0.4 (0.05–1.95) 0.187 
aaP 48 (56.5) 59 (44.7) 1.6 (0.89–2.88) 0.090 28 (45.9) 46 (43.8) 1.1 (0.54–2.15) 0.793 1 (9.1) 16 (47.1) 0.1 (0.00–0.98) 0.024 
ORF3 64 (75.3) 84 (63.6) 1.7 (0.91–3.37) 0.071 37 (60.7) 63 (60.0) 1.0 (0.51–2.06) 0.933 5 (45.5) 21 (61.8) 0.5 (0.10–2.53) 0.341 
capU 59 (69.4) 72 (54.6) 1.9 (1.02–3.51) 0.028 42 (68.9) 62 (59.1) 1.5 (0.75–3.18) 0.208 7 (63.6) 24 (70.6) 0.7 (0.14–4.20 0.665 
aar 62 (72.9) 98 (74.2) 0.9 (0.48–1.82) 0.831 42 (68.9) 70. (66.7) 1.1 (0.53–2.32) 0.772 6 (54.6) 20 (58.8) 0.8 (0.17–4.24) 0.802 
aafC 3 (3.5) 7 (5.3) 0.7 (0.10–2.96) 0.543 3 (4.9) 6 (5.7) 0.9 (0.13–4.18) 0.827 1 (9.1) 3 (8.8) 1.0 (0.01–14.6) 0.978 
agg3/4C 34 (40.0) 51 (38.6) 1.1 (0.58–1.91) 0.840 20 (32.8) 33 (31.4) 1.1 (0.50–2.19) 0.856 4 (36.4) 12 (35.3) 1.0 (0.18–5.18) 0.948 
agg3A 3 (3.5) 18 (13.6) 0.2 (0.04–0.83) 0.014 5 (8.2) 8 (7.6) 1.1 (0.26–3.96) 0.893 2 (18.2) 2 (5.9) 3.6 (0.22–53.6) 0.212 
aafA 1 (1.2) 3 (2.3) 0.3 (0.01–6.51) 0.557 2 (3.3) 10 (9.5) 0.3 (0.03–1.59) 0.134 0 (0) 2 (5.9) 0.0 (0.00–16.8) 0.410 
aggA 32 (37.7) 28 (21.2) 2.2 (1.16–4.29) 0.008 13 (21.3) 25 (23.8) 0.9 (0.37–1.95) 0.711 2 (18.2) 9 (26.5) 0.6 (0.05–3.94) 0.578 
agg4A 10 (11.8 12 (9.1) 1.3 (0.48–3.55) 0.524 4 (6.6) 2 (1.9) 3.6 (0.49–40.7) 0.121 1 (9.1) 2 (5.9) 1.6 (0.02–33.4) 0.710 
astA 46 (54.1) 55 (41.7) 1.7 (0.91–2.96) 0.072 41 (67.2) 52 (49.5) 2.1 (1.03–4.27) 0.026 4 (36.4) 22 (64.7) 0.3 (0.05–1.56) 0.098 
sat 20 (23.5) 24 (18.2) 1.4 (0.66–2.84) 0.338 9 (14.8) 24 (22.9) 0.6 (0.22–1.43) 0.207 0 (0) 8 (23.5) 0.0 (0.00–1.69) 0.076 
sepA 31 (36.5) 35 (26.5) 1.6 (0.84–2.86) 0.119 16 (26.2) 23 (21.9) 1.3 (0.56–2.79) 0.526 3 (27.3) 4 (11.8) 2.8 (0.33–20.1) 0.217 
pet 15 (17.7) 4 (3.0) 6.9 (2.06–29.20) < 0.001 9 (14.8) 16 (15.2) 1.0 (0.34–2.51) 0.933 0 (0) 4 (11.8) 0.0 (0.00–4.78) 0.233 
pic 24 (28.2) 34 (25.8) 1.1 (0.58–2.18) 0.687 28 (45.9) 41 (39.1) 1.3 (0.66–2.63) 0.387 3 (27.3) 13 (38.2) 0.6 (0.08–3.18) 0.509 
sigA 4 (4.7) 5 (3.8) 1.3 (0.24–6.01) 0.740 10 (16.4) 20 (19.1) 0.8 (0.32–2.04) 0.668 4 (36.4) 6 (17.7) 2.7 (0.42–15.0) 0.194 
aaiC 22 (25.9) 34 (25.8) 1.0 (0.51–1.95) 0.983 19 (31.2) 48 (45.7) 0.5 (0.25–1.09) 0.065 3 (27.3) 15 (44.1) 0.5 (0.07–2.47) 0.321 
air 26 (30.6) 34 (25.8) 1.3 (0.66–2.32) 0.437 13 (21.3) 21 (20.0) 1.1 (0.45–2.50) 0.840 2 (18.2) 2 (5.9) 3.6 (0.22–53.6) 0.212 
eilA 37 (43.5) 54 (40.9) 1.1 (0.61–2.00) 0.702 35 (57.4) 52 (49.5) 1.4 (0.69–2.72) 0.328 7 (63.6) 22 (64.7) 1.0 (0.19–5.38) 0.948 
CI = confidence interval; EAEC = enteroaggregaive Escherichia coli; OR = odds ratio. 
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TABLE 4 
Antimicrobial-resistant pattern of EAEC strains (N = 88) 
Antibiotics (µg) Resistant no. (%) 
Susceptible no. 
(%) 
Sulphamethoxazole-
trimethoprim (25) 75 (85.0) 13 (15.0) 
Ampicillin (10) 63 (72.0) 25 (28.0) 
Chloramphenicol (30) 16 (18.2) 72 (81.8) 
Nalidixic acid (30) 16 (18.2) 72 (81.8) 
Ciprofloxacin (5) 8 (9.0) 80 (91.0) 
Cefotazidime (30) 2 (2.3) 86 (97.7) 
Ceftriaxone (30) 0 (0) 88 (100) 
Cefoxitin (30) 0 (0) 88 (100) 
EAEC = enteroaggregaive Escherichia coli. 
SUPPLEMENTAL FIGURE 1. Association of virulence factors with diarrhea in children aged 0–59 months. Each 
branch of the Classification and Regression Tree ends in a terminal “node” (red boxes), and each terminal node 
is uniquely defined by the presence or absence of a predictive factor such as a gene or virulence factor score. 
SUPPLEMENTAL FIGURE 2. Association of virulence factors with diarrhea in children aged 0–11 months. Each 
branch of the Classification and Regression Tree ends in a terminal “node” (red boxes), and each terminal node 
is uniquely defined by the presence or absence of a predictive factor such as a gene or virulence factor score 
(VFS). 
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